Macroaxis: Personalized Investing
Simple Personalized Investing

S&P 500   1,666   1.71  Index Moved Down -0.1%
FNMFO FNMFO 096770 KDDIF Copper Railroads Software Index Choice 
United States  USA  |  Investing Opportunities


Processing
Collecting data for BIOC

BioClinica quote and profile

 
 Companies |  Insiders  | Dashboard  
     
7.28
  
STOCK
0.00  No Change   0.00%  
May 20 2013 

Diversification Suggestion

Use BioClinica to protect against small markets fluctuations. The stock experiences normal downward trend, but the immediate impact on correlations cannot be determined at the moment
Check current 30 days BioClinica correlation with market (S&P 500)
1 Month Beta 0.0  
Unless we do not have data at the moment the returns on S&P 500 and BioClinica are completely uncorrelated
BioClinica Inc not significant BetaBioClinica Inc Beta Legend
BIOC United States Nasdaq
BioClinica Inc
http://www.bioclinica.com
Contact Number: 267. 757. 3000
Traded on NASDAQ General Markets
    
Current Valuation104.18 M
Shares Outstanding15.6 M
Number of Shares Shorted12.14 K
Revenue79 M
 United States Nasdaq   0.97 % Macroaxis: 0.97 Moved Up  
 
 United States NYSE   0.12 % Macroaxis: 0.12 Moved Up  
 
 United States Russel   0.09 % Macroaxis: 0.09 Moved Up  
 
 thisGreen BIOC BIOC agains markets  0.00 % No Change  
 United States SP 500   0.10 % Macroaxis: 0.1 Moved Down  
 
Compare to Competition Get Alpha   Get Advice

BioClinica Leadership

Mark Weinstein CEO and President and Executive Director, MBA
David Nowicki Independent Chairman of the Board
Amro Majid Chairman of the Board and Managing Director, representing Glaxo Group Ltd.
Peter Benton Executive VP and President of eClinical Division, MBA

BioClinica Summary

BioClinica Inc [BIOC] is traded on NASDAQ General Markets in USA. It is located in BioClinica, Inc.Newtown, PA and employs 522 people. The company currently falls under 'Small-Cap' category with current market capitalization of 112.97 M. BioClinica Inc has 15.6 M outstanding shares of which 12.14 K shares are currently shorted by private and institutional investors with about 1.2 trading days to cover.
BioClinica, Inc. offer integrated clinical research technology solutions to pharmaceutical, biotechnology, and medical device companies. more
Follow BioClinica with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add BioClinica to your reader
 

BioClinica Research Report

BioClinica vs. Federal

Correlation analysis and fundamentals comparison between BioClinica Inc and Federal National Mor

BioClinica Executives

Ted CPA CFO, Principal Accounting Officer, Executive VP of Fin. and Admin. and Secretary
Mohammed Ibrahim CFO and Member of the Board, representing Glaxo Group Ltd.
Garry Johnson CTO and Executive VP

BioClinica Directors

Jeffrey Berg Independent Director, MBA
Marcella LoCastro Independent Director
Adil Yousef Director of Investor Relations, IR Contact Officer
E Davidoff Independent Director
Adel Yousef Director of Investor Relations

BioClinica Management

Jonathan Andrus Sr. VP of Operations
Tariq Khaliq Executive Member of the Board, representing Glaxo Group Ltd.
Sherine Ansari Non-Executive Member of the Board, representing Al Ahly Societe General Bank

BioClinica Fundamentals

Current Asset vs Price to Earnings To Growth
Gross Profit vs Total Debt
Current Asset vs Price to Earning
Current Valuation vs Total Debt

 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium